TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA expanded approval of phentolamine ophthalmic solution 0.75% (Ryzumvi) to include presbyopia, according to its manufacturers, Opus Genetics and Viatris. In the VEGA-3 trial, 27% of treated participants met the primary near-vision endpoint, compared with 12% receiving placebo; the findings do not establish how long benefits persist in routine use.
The FDA expanded approval of Ryzumvi, a 0.75% phentolamine ophthalmic solution, to include treatment of presbyopia, the age-associated difficulty focusing on nearby objects, according to manufacturers Opus Genetics and Viatris. The change gives adults another prescription eye-drop option for near-vision impairment; the companies say the drops are designed to improve near vision while preserving distance vision.
The expanded indication was supported by two phase III studies, VEGA-2 and VEGA-3, both of which met their primary endpoints, according to the report. VEGA-2 evaluated phentolamine drops in combination with topical pilocarpine against placebo. VEGA-3 tested phentolamine alone against placebo. The available report provides detailed results for VEGA-3, but not numerical outcomes for VEGA-2.
VEGA-3 enrolled 569 adults ages 40 to 64 whose binocular, photopic distance-corrected near visual acuity was 20/50 or worse. Participants were assigned to nightly 0.75% phentolamine drops or placebo. The primary endpoint measured the share who gained at least three lines on the near-vision chart while losing fewer than five letters in best-corrected distance vision on day eight, 12 hours after dosing.
That endpoint was reached by 27% of participants receiving phentolamine, compared with 12% on placebo (P<0.0001), the reported results show. A statistically significant difference was also reported within the first hour after dosing: 21% versus 6% (P<0.001). These are trial results at specified assessment times, not a measure of how every patient will respond or how well the drops work over longer periods.
Another Prescription Option for Near Vision
The FDA action adds a different active ingredient and approach to a prescription market that already includes several approved drops for presbyopia. For people seeking help with near tasks such as reading, an additional approved option may broaden discussions with an eye-care professional. The trial’s primary endpoint also tracked whether near-vision improvement came with a meaningful loss in measured distance acuity, making the balance between those outcomes part of the evidence presented.
The findings should be read in their study context: 27% met the specified endpoint in VEGA-3, compared with 12% on placebo, and the assessment was made on day eight. That result does not mean all users will experience improved vision, nor does it by itself establish long-term effectiveness, daily-life benefit, or how Ryzumvi compares directly with other approved products. The source material does not provide such comparisons.
Safety information also affects who may be a candidate. The companies state that Ryzumvi is not recommended for people with active ocular inflammation. The reported trial adverse events were mostly mild and transient, but patients considering treatment need product-specific guidance from a qualified eye-care professional rather than relying on trial averages alone.
As an affiliate, we earn on qualifying purchases.
Ryzumvi’s Earlier FDA Indication
Ryzumvi had previously been approved for mydriasis—abnormal or persistent pupil dilation induced by adrenergic agonists or parasympatholytic agents—in adults and children aged three and older. The presbyopia decision adds a separate use. The reported mechanism is sympatholytic: the drops reduce pupil dilation without acting on the ciliary muscle, according to the source material.
The FDA has approved other prescription drops for presbyopia in recent years. The report lists Vuity (pilocarpine hydrochloride 1.25%), approved in 2021; Qlosi (pilocarpine hydrochloride 0.4%), approved in 2023; Vizz (aceclidine 1.44%), approved in 2025; and Yuvezzi (carbachol and brimonidine tartrate), approved earlier in 2026. Ryzumvi therefore joins an existing set of treatments rather than entering a category with no approved drops.
“The FDA expanded approval of phentolamine ophthalmic solution 0.75% (Ryzumvi) to include presbyopia.”
— Opus Genetics and Viatris, as reported by MedPage Today
As an affiliate, we earn on qualifying purchases.
Longer-Term Results Remain Unreported
The source material does not give the full FDA label, including complete directions, warnings, or the details of every approved-use condition. It also does not report VEGA-2’s numerical results, the duration of benefit beyond the cited assessments, or whether additional follow-up data are available. The reported VEGA-3 figures describe a trial population and defined endpoint, so they do not establish an individual patient’s likely response.
It is also unclear from the supplied report how Ryzumvi’s price, insurance coverage, or availability will compare with other prescription drops. No head-to-head trial results against those products are provided. The reported adverse-event list is not a substitute for the complete prescribing information.
As an affiliate, we earn on qualifying purchases.
Full Label and Access Details
The next practical step for patients and clinicians is review of the FDA-approved prescribing information for the expanded indication, including dosing instructions, warnings, and eligibility. The source material does not specify a launch date, pricing, or coverage arrangements for the presbyopia use, so those details remain to be confirmed. Clinicians can discuss whether the treatment fits an individual’s eye health and vision needs.
People using contact lenses should follow the companies’ instructions: remove lenses before applying the drops and wait 10 minutes before putting them back in. The vial tip should not touch the eye, to reduce the risk of injury or contamination. The company guidance also advises against use in people with active ocular inflammation.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve Ryzumvi to treat?
The FDA expanded Ryzumvi’s approval to include presbyopia, according to manufacturers Opus Genetics and Viatris. It was previously approved for certain cases of drug-induced mydriasis, or pupil dilation.
How did Ryzumvi perform in the VEGA-3 trial?
On day eight, 27% of participants using phentolamine met the trial’s primary endpoint, compared with 12% receiving placebo. The endpoint required a gain of at least three lines in near vision with less than a five-letter loss in best-corrected distance vision.
What side effects were reported?
Reported adverse events were mostly mild and transient. The most common listed were conjunctival hyperemia (26%) and instillation-site irritation (15%); eye irritation, dysgeusia, and headache were also reported. Consult a qualified eye-care professional for advice about individual risks.
Who should not use Ryzumvi, according to the companies?
The companies state that Ryzumvi is not recommended for people with active ocular inflammation. The complete prescribing information should be reviewed with an eye-care professional.
What should contact lens wearers do?
Company guidance says to remove contact lenses before applying the drops and wait 10 minutes before reinserting them. The vial tip should not touch the eye.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
